Floatz logo

su011248

Adenocarcinoma of the Pancreas

OHSU Knight Cancer InstitutePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

17 Active assets in the Adenocarcinoma of the Pancreas cohort.

Asset / SponsorPhaseRating
Docetaxel
Bristol-Myers Squibb
Phase 2BBB
(+)-VINCRISTINE
Georgetown University
Phase 3BBB
Cediranib
University Health Network, Toronto
Phase 3BB
azd6244
AstraZeneca
Phase 2BB
Veliparib
National Cancer Institute (NCI)
Phase 2BB

View all 47 →

Same molecule, other indications

su011248 is also rated in:

Gastrointestinal Stromal TumorsDormant
BBB
Indicative ·
75 / 100
View asset →
Pancreatic Neuroendocrine TumorDormant
BB
Indicative ·
69 / 100
View asset →
Renal Cell CarcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →